HR+/HERX- made have we teams Thank for second XX quarter, programs positive such long-term you, HDV. pre-treated our OS overall X medical with in Joanna. Yescarta as or refractory I'm tied ongoing to data for Trodelvy updated and large data trails. highlight the cancer, blabber data lymphoma, Phase metastatic presented Notably, the breast XX ongoing conferences pleased second-line in multiple at B-cell clinical progress from survival and in relapsed data readouts in
move execution, into focused investing we and to in XXXX, capabilities second portfolio on remain the As half productivity of we prioritization. our increase
We also non-small at September. update look-forward in data cancer, an sharing on including Lung on Conference lung Cancer World cell in EVOKE-XX to Trodelvy
are in care. Turning slide we Gilead first of to has proud played Virology role the XX, HIV transforming on
work prevention innovate regimen eight programs, HIV and community our of inhibitor those and new to both capsid effective do convenient The the focused We lenacapavir, with continue to profile clinical we're on our prevention options. treatment from unique first-in class ongoing could based who commitment and our the to benefit on. to enables over
and oral bictegravir trial daily ARTISTRY-X progressing In It's well. the HIV combination evaluating lenacapavir treatment regimen. once your
of the later for an simpler biologically provide aims to regimens to X% X% who and expect provide X This to portion the We an on multi the novel a to Phase complex HIV. this year. suppressed update individuals effective their on regimen tablet study currently are regimen manage
well as X through our regimens providing options the inhibitors, broadly of the HIV and study integrase goal of longer-acting We continue antibodies. lenacapavir treatment neutralizing advance to combination as NRTIs development two with of our Phase NNRTI in
recruitment early the six X single-agent approval months Phase timeframe subcutaneous prevention, late XXXX, HIV look-forward expectations quarter. a evaluating In target in for in PURPOSE-X/-X We clinical update to in lenacapavir our to continues potentially trials to XXXX as XXXX. second every our data late we providing exceed
Study antiviral the should Moving or XX, for note EU in slide HDV to I'm of for guidelines the its to infection, updated pleased considered to that treatments. that on recommend HDV Association all EASL Liver the patients be with European has chronic the
commission were European Journal XX-week the in in the by Recently the June. Hepcludex by approval published guidelines data of which chronic New HCV only remains was supported granted approved full the in Hepcludex were 's The for infection EU. therapy Medicine updated England
with and non potentially Gilead who partial reinforce including also our confidence treatment data no XX-week in with resistance, for data presented treatment-emergent with biologic its improved demonstrating of bulevirtide or the biochemical were evidence responders. those responses patients previously bulevirtide benefit longer-term HDV. and These
bulevirtide reminder, the US. not approved a in As is yet
increasing over low disease. trials. on for ADC three a dataset approved more Trodelvy's discontinuation benefit two We've robust now tumor clinical and TROPX-directed evaluate safety indications overall Oncology no interstitial observed in multiple to Turning required ADC treated severe types. our indications and than TROPX-directed only rates across only slide lung the Trodelvy XX,XXX patients patients show across tumor also first with profile XXXX remains types. monitoring with informs well-characterized and in survival It's the to versus chemotherapy XX.
additional cancer. our At supporting pre-treated presented authorization European X including breast final we last in the received We trial metastatic potential, TROPiCS-XX data week. ASCO, Phase Commission Trodelvy's from analysis presented the demonstrating the just HR+/HERX- we from marketing
expanding bladder Trodelvy's in from confirmatory cancer, supporting urothelial X Phase of trial, trail efficacy provide a approval In TROPHY-U-XX end In expression. pan-tumor With an our in global Trodelvy urothelial ongoing range TROPiCS-XX heavily of Basket cancer next of demonstrating Phase initiate efficacy analysis TROP-X update accelerated data from metastatic a filings of data potential post-IO we bladder pre-treated cancer, our promising to the across shared for we TROPiCS-XX in cancer endometrial hope we Trodelvy. metastatic the the presented cancer, X by and post-platinum year.
the Moving is unmet program the an signal-seeking significant XX, death, believe well cancer-related of but trials. comprehensive as includes single-agent clinical the backbone also in as lung in only an and has a as Phase setting. of transform to Trodelvy first-line several we X cancer to to standard-of-care IO area not a know lung our cause slide development non-small clinical cell in non-small ongoing partner We number-one cancer as an potential combination post-IO the need, area cell setting,
new from particularly XX, of catalysts. at added World on highlight slide lung-related Conference Lung Phase number growing the X a milestone that to EVOKE-XX we've readout a we the highlight excited On trial our with I'm preliminary Cancer.
non-small cell with cancer. evaluating or without in chemo This Trodelvy study pembrolizumab, is plus lung first-line
with two of PD-LX in initial patients. evaluating data in low We abstract, high subset of cohorts be and released from be will sharing to number small the The PD-LX August, first combination expected Trodelvy in pembro patients. an later will a be
September presentation Our patients. for date cut-off more with World at data scheduled Lung will include later Sunday, a XXth at
XX, ASCO clinically enrolled analysis in Turning to data in ARC-X the agent for or survival PDX progression-free trials cell inhibitor interim Phase the dom, an encompassing as and the cancers. data to program domvanalimab, The slide GI June. These patients of at first-line the form improvement we is study last anti-PDX investigational basis in presented data from cell full non-small in XXX and PD-LX our consistent dom, to X X on cancer show continued cancer, Phase dom with non-small alone. compared our high in anti-TIGIT first-line Fc-silent lung when upper lung combined the meaningful
data Yescarta from lymphoma. Moving cell therapy Phase slide B-cell the presented in therapy on trial to relapsed Yescarta B-cell of position large to overall June, X for its or refractory cell in choice we ZUMA-X ASCO XX. survival a At as strengthen lymphoma. landmark large of continues second-line
in standard-of-care a longer a therapy of cell relative compared statistically a four reduction with significant the death, a the received XX% eventually improvement. treatment At patients of overall risk demonstrated survival of follow-up a to with arm the Yescarta off Moreover, XX% one-time majority protocol. median representing years, in standard-of-care a
this received potentially Overall, XX% some curative significant demonstrate in that those, of Yescarta these treatment of to patient first nearly And is Yescarta. in growing for to population, add therapy as improvement data cell the in the evidence and a populations. years body position XX survival
the of With and strong and trials of assets, and lines benefit cell X therapy, of potential new innovation acquired across through new Kite pipeline types, collaborations. on X innovate Phase continues patients, expanding through therapies six and internal a or both execute tumor to ongoing to earlier-stage
support and patients. are confident these hold. regarding CAR-T Arcellx's trial We to partners, novel to We on based delivering Arcellx, the one for the working of in their IMAGINE-X clinical data sharing demonstrated therapeutic to profile myeloma closely remain with and multiple IMAGINE-X efforts ddBCMA commitment to therapy the date, this
for our slide clinical so against key to milestones far. highlight progress Turning XX, we XXXX
We disappointed are of the treatment analysis need for of evaluating trial magrolimab in course given ENHANCE outcome the options. MDS, of by higher-risk the interim the
to magrolimab monitor continue other the report will and We on trials.
every positive, making portfolio continue at strong efforts the contributors key building for multiple oncology us our be momentum while inflammation to and in our year. patients. Importantly, progress of lives our We're a catalysts improve trial about gives to this not make and delivering excited important on clinical will well-diversified opportunities our future to
early-stage like X growing Beyond program that Phase asserted our of beta the our inhibitor into of progression acquisition IRAKX inflammation Phase assets, as advancement also our into alpha BTLA the the I'd from to highlight X. our pipeline the and milestones, had as including X, of oral agonist MiroBio near-term well X
We as treatment have important impact diseases. the we gaps potential you the pipeline are XXXX. to to across this we indications of forward through inflammation and is progress very look well-diversified in Overall, by clinical a differentiated and ambitious We inflammatory we portfolio stage. excited believe that updating
over hand I'll call Andy? the to Andy. With that
